Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders. According to the company’s public disclosures, Xtant centers its business on the design, development, and commercialization of a portfolio of orthobiologics that serve the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The company repeatedly describes its mission as honoring the gift of donation so that patients can live as full and complete a life as possible, which is presented as the driving force behind its operations.

Business focus and product portfolio

Xtant states that it offers a comprehensive portfolio of orthobiologics and related products used in surgical procedures for spinal and other orthopedic conditions, chronic and surgical wound care, and sports medicine. Company communications describe Xtant as a medical technology and regenerative medicine firm with capabilities that include the development and manufacture of orthobiologic products. In multiple releases, Xtant notes that it is one of the few fully vertically integrated regenerative medicine firms, and that it develops and manufactures solutions across major orthobiologic categories.

The company highlights several named products within its biologics and synthetic graft portfolio. These include:

• CollagenX™, a bovine collagen particulate product for surgical wound closure that is designed to promote healing, prevent dehiscence, and help address concerns related to surgical site infections. Xtant describes CollagenX as a potential addition to every case type currently addressed by its biologics portfolio, as well as procedures in other surgical disciplines.
• OsteoFactor Pro™, described as a naturally occurring cocktail of allogeneic growth factors engineered and designed to improve bone healing and support surgical success across orthopedic and spine procedures.
• Trivium™, characterized as a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures.
• nanOss Strata™, a next-generation synthetic bone graft in the nanOss line, manufactured from hydroxycarbonapatite (HCA). Company materials state that HCA has higher solubility than traditional hydroxyapatite and that the nanocrystalline structure used in nanOss Strata is designed to closely mimic human bone, increase surface area for osteoconductivity, and stimulate cellular activity on the graft surface after implantation. Strata is offered in compression-resistant preformed strips and prehydrated moldable grafts.

In addition to these products, Xtant’s previously supplied description (via Polygon data) notes that the company has developed a portfolio of orthobiologics and spinal implant systems used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders. That description lists biomaterial products such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, as well as other allografts, and indicates that a majority of revenue has historically been generated in the United States. While this external description may predate some recent strategic changes, it is consistent with the company’s repeated emphasis on orthobiologics and spinal solutions.

Strategic focus on core biologics and divestiture of non-core assets

Recent SEC filings and press releases describe a strategic effort to sharpen Xtant’s focus on its core biologics business. On July 7, 2025, the company entered into an Asset Purchase Agreement and an Equity Purchase Agreement to sell certain Coflex® and CoFix® spinal implant assets in the United States and all shares of Paradigm Spine GmbH, which operated the company’s hardware business outside the United States. An 8-K filed on December 3, 2025 reports that these divestitures were completed on December 1, 2025, transferring the Coflex/CoFix assets and Paradigm Spine GmbH to Companion Spine entities.

In related news releases, Xtant characterizes these Coflex and Paradigm businesses as non-core and states that the sale allows the company to enhance its focus on its core biologics business, reduce debt, and improve its balance sheet. Management commentary in quarterly results further links this strategic shift to an emphasis on self-sustainability, positive cash flow, and the continued development of advanced biologic products.

Operations, integration, and markets served

Across multiple communications, Xtant describes itself as a global medical technology company with a portfolio that serves spinal, orthopedic, and wound care disorders, and orthobiologics that support chronic and surgical wound care and sports medicine markets, alongside spinal implant systems. The company notes that its biologics portfolio can be used across a wide range of case types and surgical disciplines, and that products such as CollagenX are intended to be applicable to procedures already addressed by its biologics range as well as other surgical areas.

Xtant also states that, with the launch of OsteoFactor Pro, it is the only vertically integrated company to develop and manufacture solutions across all major orthobiologic categories, underscoring its emphasis on internal development and manufacturing capabilities within regenerative medicine. The company’s people are described as dedicated and talented, operating with a focus on integrity in serving customers.

Corporate governance and shareholder base

Xtant Medical Holdings, Inc. is incorporated in Delaware and files periodic reports, proxy statements, and current reports with the U.S. Securities and Exchange Commission. A definitive proxy statement filed on September 15, 2025 outlines the company’s corporate governance structure, including its Board of Directors, board committees, and governance policies. The proxy materials describe an annual meeting of stockholders held on November 7, 2025, at which stockholders voted on director elections, auditor ratification, an amendment to the 2023 Equity Incentive Plan, and advisory votes on executive compensation and the frequency of such votes.

An 8-K filed on August 4, 2025 details changes to the Board, including the election of new directors with backgrounds in investment management and orthobiologics, orthopedics, and spine industries. The filing also notes that funds affiliated with Nantahala Capital Management, LLC became significant stockholders through a privately negotiated stock purchase from former majority stockholders, and that the company entered into a registration rights agreement with these purchasers.

Financial reporting and performance communication

Xtant regularly reports its financial and operating results through press releases and Form 8-K filings. For example, releases covering the second and third quarters of 2025 describe revenue growth, changes in gross margin, net income, adjusted EBITDA, and operating cash flow, as well as the impact of licensing revenue and product mix. These communications also reference the company’s use of non-GAAP adjusted EBITDA as a supplemental measure of operational performance, with reconciliations provided in accompanying tables.

The company’s balance sheet data, included in quarterly results, show categories such as cash and cash equivalents, trade accounts receivable, inventories, property and equipment, goodwill, intangible assets, accounts payable, accrued liabilities, lease liabilities, long-term debt, and stockholders’ equity. Xtant also provides financial guidance for full-year revenue and discusses factors that may affect future performance, while cautioning that forward-looking statements involve risks and uncertainties described in its Annual Report on Form 10-K and subsequent SEC filings.

Mission and values

In each of its recent press releases and corporate descriptions, Xtant reiterates that its mission of honoring the gift of donation so that patients can live as full and complete a life as possible is central to the company’s identity. This mission is linked to its work in regenerative medicine and orthobiologics, and to its stated commitment to innovation, quality, and integrity in serving surgeons, patients, and other stakeholders.

Frequently asked questions (FAQ)

What does Xtant Medical Holdings, Inc. do?
According to its public disclosures, Xtant Medical is a global medical technology company focused on the design, development, and commercialization of a portfolio of orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems used in surgical solutions for spinal and other orthopedic conditions.

What is Xtant’s core business focus?
Company filings and news releases describe a strategic focus on its core biologics business. Xtant emphasizes orthobiologic products and regenerative medicine solutions, and has completed the sale of certain non-core Coflex and CoFix spinal implant assets and its international hardware business to concentrate on this core area.

Which markets and conditions does Xtant target?
Xtant states that it focuses on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders. Its orthobiologics portfolio serves chronic and surgical wound care and sports medicine markets, and its products are used in procedures across orthopedic and spine applications.

What are some of Xtant’s key products?
Recent company announcements highlight products such as CollagenX (a bovine collagen particulate for surgical wound closure), OsteoFactor Pro (a growth factor-based product designed to improve bone healing), Trivium (a next-generation DBM allograft), and nanOss Strata (a synthetic bone graft manufactured from hydroxycarbonapatite). Earlier descriptions also reference products like OsteoSponge and related biomaterials.

How has Xtant changed its portfolio through divestitures?
An 8-K filed on December 3, 2025 reports that on December 1, 2025 Xtant completed the sale of certain Coflex and CoFix product assets in the United States and all shares of Paradigm Spine GmbH, its international hardware business, to Companion Spine entities. Company commentary describes these as non-core businesses and indicates that the sale is intended to sharpen focus on biologics and improve the balance sheet.

How does Xtant describe its role in regenerative medicine?
In its second quarter 2025 results release, Xtant states that, with the launch of OsteoFactor Pro, it is one of the few fully vertically integrated regenerative medicine firms and the only vertically integrated company to develop and manufacture solutions across all major orthobiologic categories, underscoring its emphasis on internal development and manufacturing capabilities.

Where is Xtant Medical listed and what is its ticker symbol?
The company’s releases identify Xtant Medical Holdings, Inc. as trading on the NYSE American exchange under the symbol XTNT.

How does Xtant communicate financial performance to investors?
Xtant issues quarterly press releases and files Form 8-Ks to report financial and operating results, including revenue, gross margin, net income or loss, adjusted EBITDA, and cash flow. It also provides financial guidance for full-year revenue and explains its use of non-GAAP measures such as adjusted EBITDA, with reconciliations to GAAP metrics.

What corporate governance information is available?
The company’s definitive proxy statement on Schedule 14A for its 2025 annual meeting describes its Board of Directors, board committees, corporate governance guidelines, director compensation, executive compensation, and matters submitted to stockholders, including amendments to its equity incentive plan and advisory votes on executive pay.

What is Xtant’s stated mission?
In repeated “About Xtant Medical” sections, the company states that its mission of honoring the gift of donation so that patients can live as full and complete a life as possible is the driving force behind the company.